Nuciferine protects against folic acid‐induced acute kidney injury by inhibiting ferroptosis

Danyu Li,Bing Liu,Yumei Fan,Ming Liu,Bihui Han,Yanxiu Meng,Xiao Xu,Zhiyuan Song,Xiaopeng Liu,Qiang Hao,Xianglin Duan,Akira Nakai,Yanzhong Chang,Pengxiu Cao,Ke Tan
DOI: https://doi.org/10.1111/bph.15364
IF: 7.3
2021-02-10
British Journal of Pharmacology
Abstract:Background and PurposeAcute kidney injury (AKI) is a common clinical problem with no definitive or specific treatment. Therefore, the molecular mechanisms of AKI must be elicited to develop novel treatments. Nuciferine, a major bioactive compound isolated from the lotus leaf, possesses extensive pharmacological activities. Its effect on folic acid (FA)‐induced AKI, however, remains unknown. Here we aimed to clarify the pharmacological effects of nuciferine and underlying mechanisms in AKI. Experimental ApproachThe effects of nuciferine on FA‐induced AKI in mice were investigated. HK‐2 human proximal tubular epithelial cells and HEK293T human embryonic kidney cells were used to evaluate the protective effect of nuciferine on RSL3‐induced ferroptosis. Key ResultsNuciferine treatment mitigated the pathological alterations, ameliorated inflammatory cell infiltration and improved kidney dysfunction in mice with FA‐induced AKI. In HK‐2 and HEK293T cells, nuciferine significantly prevented RSL3‐induced ferroptotic cell death. Mechanistically, nuciferine significantly inhibited ferroptosis by preventing iron accumulation and lipid peroxidation in vitro and in vivo. Moreover, knockdown of glutathione peroxidase 4 (GPX4) abolished the protective effect of nuciferine against ferroptosis. Conclusions and ImplicationsNuciferine ameliorated renal injury in mice with AKI, perhaps by inhibiting the ferroptosis. Nuciferine may represent a novel treatment that improves recovery from AKI by targeting ferroptosis.
pharmacology & pharmacy
What problem does this paper attempt to address?